A randomized, double-blind, ascending dose, placebo-controlled single dose study in non-smoking healthy elderly subjects interleaved with a 2-week multiple once daily dose study to explore safety, tolerability, pharmacokinetics and cognitive effects after oral administration of AQW051

Trial Profile

A randomized, double-blind, ascending dose, placebo-controlled single dose study in non-smoking healthy elderly subjects interleaved with a 2-week multiple once daily dose study to explore safety, tolerability, pharmacokinetics and cognitive effects after oral administration of AQW051

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2013

At a glance

  • Drugs AQW 051 (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 21 Jun 2007 Status change from recruiting to completed
    • 19 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top